search
Back to results

Sodium-Endothelial Function-CKD Study

Primary Purpose

Kidney Failure, Chronic

Status
Completed
Phase
Not Applicable
Locations
United Kingdom
Study Type
Interventional
Intervention
Slow sodium
Sponsored by
St George's, University of London
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional prevention trial for Kidney Failure, Chronic focused on measuring Endothelial dysfunction, ADMA, DDAH, Sodium

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: CKD Stages 2 and 3 [= calculated creatinine clearance of 30 to 89 ml/min/1.73m2 by Cockcroft-Gault formula] 18 to 75 years old Exclusion Criteria: >3 g/24 hours of proteinuria Uncontrolled hypertension (systolic BP >160 mmHg, diastolic BP >100 mmHg on/off anti-hypertensive medication) Diabetes mellitus Tobacco smoking Total fasting cholesterol >6 mmol/L Uncontrolled heart failure or active IHD Chronic liver failure Active malignancy

Sites / Locations

  • Blood Pressure Unit, Department of Cardiac & Vascular Sciences, SGUL

Outcomes

Primary Outcome Measures

Under conditions of high (vs. low sodium intake) ...
(i) The ratio [ADMA]urine:[DMA]urine is increased
(ii) [ADMA]plasma is increased
(iii) Endothelium-dependent vasodilatation is reduced

Secondary Outcome Measures

Full Information

First Posted
August 31, 2005
Last Updated
May 14, 2007
Sponsor
St George's, University of London
Collaborators
British Heart Foundation, St. George's Hospital Charitable Foundation
search

1. Study Identification

Unique Protocol Identification Number
NCT00141622
Brief Title
Sodium-Endothelial Function-CKD Study
Official Title
Does Sodium Affect Endothelial Function in Individuals With Chronic Kidney Disease?
Study Type
Interventional

2. Study Status

Record Verification Date
August 2005
Overall Recruitment Status
Completed
Study Start Date
April 2005 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
October 2006 (undefined)

3. Sponsor/Collaborators

Name of the Sponsor
St George's, University of London
Collaborators
British Heart Foundation, St. George's Hospital Charitable Foundation

4. Oversight

5. Study Description

Brief Summary
Heart disease and stroke, known as cardiovascular disease, are major causes of death in people with chronic kidney disease. Abnormalities of a metabolic pathway called the "L-arginine-nitric oxide" pathway are thought to be particularly important in these people, and previous research in animals has suggested that sodium (salt) affects part of this metabolic pathway. The purpose of our research is to study the effects of sodium intake on the "L-arginine-nitric oxide" pathway, and on blood vessel function, in patients with kidney disease.
Detailed Description
Chronic kidney disease (CKD) is associated with abnormalities of endothelial function (EF) and nitric oxide (NO) synthesis, and it is proposed that the endogenous NO synthase inhibitor asymmetrical dimethylarginine (ADMA) plays a central role. In man ADMA is largely metabolized by dimethylarginine dimethylaminohydrolase (DDAH), with some renal excretion occurring. Sodium inhibits DDAH expression in experimental animals and, given that CKD is frequently characterized by sodium retention, it would be interesting to study the effects of sodium loading on DDAH activity/expression, ADMA levels and EF in CKD patients. To answer these questions, we have designed a double-blind cross-over study employing Slow Sodium (150 mmol/day) and placebo for seven days in individuals with mild-to-moderate CKD. Changes in the ratio of urinary ADMA to dimethylamine (DMA, an ADMA metabolite) will be used as an marker of DDAH activity/expression. ADMA will be measured by ELISA, DMA by high performance liquid chromatography, and EF by venous occlusion plethysmography. We propose to test the following hypothesis; that in subjects with mild-to-moderate CKD under conditions of high sodium intake, as compared to low-normal sodium intake: (i) The ratio [ADMA]urine:[DMA]urine is increased (ii) [ADMA]plasma is increased (iii) Endothelium-dependent vasodilatation is reduced

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Kidney Failure, Chronic
Keywords
Endothelial dysfunction, ADMA, DDAH, Sodium

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
Double
Allocation
Randomized
Enrollment
50 (Anticipated)

8. Arms, Groups, and Interventions

Intervention Type
Drug
Intervention Name(s)
Slow sodium
Primary Outcome Measure Information:
Title
Under conditions of high (vs. low sodium intake) ...
Title
(i) The ratio [ADMA]urine:[DMA]urine is increased
Title
(ii) [ADMA]plasma is increased
Title
(iii) Endothelium-dependent vasodilatation is reduced

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: CKD Stages 2 and 3 [= calculated creatinine clearance of 30 to 89 ml/min/1.73m2 by Cockcroft-Gault formula] 18 to 75 years old Exclusion Criteria: >3 g/24 hours of proteinuria Uncontrolled hypertension (systolic BP >160 mmHg, diastolic BP >100 mmHg on/off anti-hypertensive medication) Diabetes mellitus Tobacco smoking Total fasting cholesterol >6 mmol/L Uncontrolled heart failure or active IHD Chronic liver failure Active malignancy
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Timothy WR Doulton, BSc MRCP
Organizational Affiliation
SGUL
Official's Role
Principal Investigator
Facility Information:
Facility Name
Blood Pressure Unit, Department of Cardiac & Vascular Sciences, SGUL
City
London
ZIP/Postal Code
SW17 0RE
Country
United Kingdom

12. IPD Sharing Statement

Learn more about this trial

Sodium-Endothelial Function-CKD Study

We'll reach out to this number within 24 hrs